Just noticed MannKind had some executive shuffling going on. Lauren Sabella moved into EVP of Operations role back in January 2025, but apparently she's already calling it quits with a retirement date set for mid-2025. That was quick. Anyway, Lauren Sabella's exit from the company got me thinking about how often you see these transitions in biotech. MNKD's been down about 1.82% YTD with a market cap sitting around 1.79 billion. The stock consensus is pretty bearish according to the technical ratings. Not exactly a ringing endorsement. Wonder if the leadership change signals something about the company's direction or if it's just planned succession. Either way, when you see executives like Lauren Sabella stepping away, it's worth keeping an eye on how the operations side handles the transition. Biotech moves can be unpredictable.